Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC291 in relapsed/refractory B-cell malignancies
NCT05878184Phase 1Active, not recruiting
- Sponsor
- Sana Biotechnology
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SC291 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Sana Biotechnology. Primary endpoint: Safety and Tolerability of SC291 at 24 months. Started May 2023; status: active, not recruiting.
02
Drugs
SC291
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05878184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878184.